Journal of Traditional Chinese Medical Sciences (Apr 2023)

Exploring the mechanism of Yishen Daluo decoction in the treatment of multiple sclerosis based on network pharmacology and in vitro experiments

  • Shuo Cheng,
  • Ce Zhang,
  • Qingyuan Cai,
  • Xinghua Wang,
  • Zhaoheng Liu,
  • Peng Wei,
  • Xu Wang,
  • Yan Tan,
  • Qian Hua

Journal volume & issue
Vol. 10, no. 2
pp. 186 – 195

Abstract

Read online

Objective: To explore the mechanism and related active components of Yishen Daluo decoction (YSDLD) in treating multiple sclerosis (MS). Methods: Targets of YSDLD were collected through the TCMSP, Chemistry, and TCMID databases. The MS targets were collected through OMIM, DrugBank, Gencards, TTD, and Pharmgkb databases. We built “component–target” network diagrams and protein–protein interaction (PPI) diagrams and performed topological analysis. The targets were subjected to GO and KEGG enrichment analysis. Molecular docking verification was conducted on selected targets and molecules. Finally, in vitro experiments were conducted. BV2 cells were induced by lipopolysaccharide for model establishment. CCK8 experiment was conducted to explore the effect of YSDLD and RT-qPCR technology was used to explore the expression of key targets. Results: There were 184 active components in YSDLD and 898 targets of its action. There were 940 MS targets, and 215 targets were shared by YSDLD and MS. According to the “component–target” diagram, the top five key components included quercetin, kaempferol, beta-sitosterol, stigmasterol, and naringenin. IL-6, IL-1β, TNF-α, AKT1, and VEGFA were the important targets identified by PPI network topology analysis. A total of 564 functions were identified by GO enrichment analysis (P < .01), mainly involving inflammatory response, hypoxia response, plasma membrane, neuronal cell body, protein phosphatase binding, and cytokine activity. KEGG enrichment analysis enriched 98 pathways (P < .01). YSDLD at the concentration of 20 μg/mL had no effect on BV2 cells. RT-qPCR indicated that YSDLD at the concentrations of 15 μg/mL and 20 μg/mL alleviated LPS-induced inflammatory injury and lowered the content of inflammatory factors (P < .05). Conclusion: In this paper, the network pharmacology and in vitro experiments were used to explore the potential mechanism of YSDLD in treating MS. The research provides a good basis for the development of YSDLD and drugs for MS in future.

Keywords